Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma

Oncology Reports

Volumn 38, Issue 2, 2017, Pages 899-907

  Liu, Jianhua ^a   Liu, Yahui ^a   Meng, Lingyu ^a   Liu, Kai ^a   Ji, Bai ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

DNA methylation; DNMT1; Hepatocellular carcinoma; PD L1; Sorafenib resistance

Indexed keywords

DNA; DNA METHYLTRANSFERASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; SORAFENIB; STAT3 PROTEIN; UVOMORULIN; CARBANILAMIDE DERIVATIVE; CD274 PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE 1; DNMT1 PROTEIN, HUMAN; NICOTINAMIDE; STAT3 PROTEIN, HUMAN;

ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DRUG RESISTANCE; DRUG TARGETING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE KNOCKDOWN; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; B7-H1 ANTIGEN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NF-KAPPA B; NIACINAMIDE; PHENYLUREA COMPOUNDS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 85022010830     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2017.5722     Document Type: Article

References (34)

1. Di Maio M, Daniele B and Perrone F: Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. Nat Rev Clin Oncol 6: 505-506, 2009.
2. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844, 2006.
3. Sun X, Niu X, Chen R, He W, Chen D, Kang R and Tang D: Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 64: 488-500, 2016.
4. Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, et al: In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 20: 1138-1146, 2014.
5. Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, Fan J, Cao Y, Dai Z and Zhou J:. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology 150: 1646-1658.e17, 2016.
6. Goodman A, Patel SP and Kurzrock R: PD-1-PD-L1 immunecheckpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 14: 203-220, 2017.
7. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, et al: Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34: 3119-3125, 2016.
8. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al; KEYNOTE-024 Investigators: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833, 2016.
9. Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN and Zoubeidi A: PD-L1 is highly expressed in Enzalutamideresistant prostate cancer. Oncotarget 6: 234-242, 2015.
10. Yan F, Pang J, Peng Y, Molina JR, Yang P and Liu S: Elevated cellular PD1/PD-L1 expression confers acquired resistance to cisplatin in small cell lung cancer cells. PLoS One 11: e0162925, 2016.
11. Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, et al: BET Bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep 16: 2829-2837, 2016.
12. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211: 781-790, 2014.
13. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, et al: MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352: 227-231, 2016.
14. Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO and Lee TK: Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology 62: 534-545, 2015.
15. Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (Suppl 1): S4-S11, 2005.
16. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
17. Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, Novo FJ, Calasanz MJ, Galm O, Guo M, Benitez J, et al: Cancer epigenetics and methylation. Science 297: 1807-1808, 2002.
18. Spinzi G and Paggi S: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 2497-2498, author reply 2498-2499, 2008.
19. Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and Settleman J: Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26: 207-221, 2014.
20. Zhang C, Li J, Huang T, Duan S, Dai D, Jiang D, Sui X, Li D, Chen Y, Ding F, et al: Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma. Oncotarget 7: 81255-81267, 2016.
21. Huang J, Wang Y, Guo Y and Sun S: Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 52: 60-70, 2010.
22. Chen L, Ruan Y, Wang X, Min L, Shen Z, Sun Y and Qin X: BAY 11-7082, a nuclear factor-κB inhibitor, induces apoptosis and S phase arrest in gastric cancer cells. J Gastroenterol 49: 864-874, 2014.
23. Llovet JM, Villanueva A, Lachenmayer A and Finn RS: Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12: 436, 2015.
24. Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett 367: 1-11, 2015.
25. Chen HA, Kuo TC, Tseng CF, Ma JT, Yang ST, Yen CJ, Yang CY, Sung SY and Su JL: Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. Hepatology 64: 1637-1651, 2016.
26. Liu Y, Ye X, Zhang JB, Ouyang H, Shen Z, Wu Y, Wang W, Wu J, Tao S, Yang X, et al: PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation. Oncogene 34: 5524-5535, 2015.
27. Jin B and Robertson KD: DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol 754: 3-29, 2013.
28. Min HY, Lee SC, Woo JK, Jung HJ, Park KH, Jeong HM, Hyun SY, Cho J, Lee W, Park JE, et al: Essential role of DNA methyltransferase 1-mediated transcription of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors. Clin Cancer Res 23: 1299-1311, 2017.
29. Jiang C and Gong F: DNA methyltransferase 1: A potential gene therapy target for hepatocellular carcinoma? Oncol Res Treat 39: 448-452, 2016.
30. Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, et al: TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375: 2023-2036, 2016.
31. Duncavage EJ, Uy GL, Petti AA, Miller CA, Lee YS, Tandon B, Gao F, Fronick CC, O'Laughlin M, Fulton RS, et al: Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood 129: 1397-1401, 2017.
32. Nagaya T, Nakamura Y, Sato K, Harada T, Choyke PL, Hodge JW, Schlom J and Kobayashi H: Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget 8: 8807-8817, 2017.
33. Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N and Wasik MA: STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood 108: 1058-1064, 2006.
34. Wang WB, Yen ML, Liu KJ, Hsu PJ, Lin MH, Chen PM, Sudhir PR, Chen CH, Chen CH, Sytwu HK, et al: Interleukin-25 mediates transcriptional control of PD-L1 via STAT3 in multipotent human mesenchymal stromal cells (hMSCs) to suppress Th17 responses. Stem Cell Rep 5: 392-404, 2015.